Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

A new blood test test could determine how far Alzheimer's has progressed and could also help confirm whether another ...

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide ...

The drug, gantenerumab, was abandoned by its developers, but subsequent anti-amyloid drugs lecanemab ( Leqembi) and donanemab ...

Early-onset Alzheimer’s disease progresses more rapidly and often strikes people in the prime of their lives. A new treatment ...

With two new treatments for Alzheimer’s disease approved in recent years, there’s growing hope for people at risk of the ...

Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...

Labcorp (LH) announced the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the ...

PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...